However, DPP-4 inhibitors and GLP-1 were observed to be noninferior to placebo for primary composite CV outcomes and hospitalization for HF (Scirica et al., 2013; White et al., 2013; Marso et al., 2016). This evidence concerns the gene DPP4 and hydrops fetalis.